LENZ Therapeutics does not pay cash dividends to its common shareholders, as the enterprise directs all available capital resources, operating cash flows, and commercial revenues back into ongoing research and development, sales infrastructure expansion, and market penetration strategies. Management prioritizes long-term capital appreciation and pipeline growth over short-term dividend distributions, typical of emerging pharmaceutical growth companies.